Controlled Amyloid Beta Release
Controlled Amyloid Beta Release - Related Videos
03:08
Fabrication of Amyloid-Beta-Releasing Polymer Microbeads for Modeling Alzheimer's Disease
0 Views •
2025
This video demonstrates a method for fabricating polymer microbeads that encapsulate neurotoxic amyloid-beta-secreting cells. The cell-polymer suspension is processed through a microbead fabrication device, with polymer gelation achieved via calcium cross-linking, forming spherical microbeads around the cells. The polymer allows cell proliferation while allowing controlled, long-term amyloid-beta release, simulating its accumulation in Alzheimer's disease.
11:13
Composite Scaffolds of Interfacial Polyelectrolyte Fibers for Temporally Controlled Release of Biomolecules
0 Views •
Cited by 3 •
2015
Scaffolds for tissue engineering need to recapitulate the complex biochemical and biophysical microenvironment of the cellular niche. Here, we show the use of interfacial polyelectrolyte complexation fibers as a platform to create composite, multi-component polymeric scaffolds with sustained biochemical release.
01:25
Beta
0 Views •
2024
Beta is a crucial metric in finance used to assess an investment's risk and expected return relative to the overall market. It is calculated as the slope of the line in a scatterplot that compares the returns of an individual stock to the returns of the market benchmark, typically represented by a broad market index. Beta quantifies how much a stock's price moves in response to market movements, providing insight into its volatility and systematic risk. A beta of one indicates that the stock's...
09:11
Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release
0 Views •
Cited by 10 •
2016
We present a facile method to fabricate a biodegradable gelatin-based drug release platform that is magneto-thermally responsive. This was achieved by incorporating superparamagnetic iron oxide nanoparticles and poly(N-isopropylacrylamide-co-acrylamide) within a spherical gelatin micro-network crosslinked by genipin, in conjunction with an alternating magnetic field application system.
11:53
Predicting Gene Silencing Through the Spatiotemporal Control of siRNA Release from Photo-responsive Polymeric Nanocarriers
0 Views •
Cited by 6 •
2017
We present a novel method that uses photo-responsive block copolymers for more efficient spatiotemporal control of gene silencing with no detectable off-target effects. Additionally, changes in gene expression can be predicted using straightforward siRNA release assays and simple kinetic modeling.
FAQs
Sequential cleavage creates two experimental control points. Beta-secretase acts first on amyloid precursor protein, and gamma-secretase follows, so changing either step can alter the amount of Aβ available for secretion. Examining these steps separately helps distinguish effects of amyloid processing from effects caused by later movement through secretory or endosomal pathways.
Neuronal activity can make Aβ release activity-dependent rather than constant. By changing activity conditions in neurons or model systems, investigators can compare peptide secretion during different functional states and then examine associated signaling or synaptic consequences. This links release dynamics to neuroscience questions about how cellular activity may influence Aβ accumulation and synaptic dysfunction.
Vesicle trafficking determines where newly generated peptide travels before it exits the cell. Secretory and endosomal routes therefore provide distinct cellular contexts for studying release control, rather than treating secretion as a single step. Following how trafficking conditions affect peptide movement can help identify circumstances associated with accumulation or aggregation.
A controlled experiment can vary one release regulator at a time, such as neuronal activity, secretase function, or vesicle trafficking, while keeping the model system consistent. Comparing the resulting release conditions creates a framework for assigning changes in Aβ-related signaling, accumulation, or synaptic dysfunction to the manipulated process rather than to the model alone.
It provides a way to test interventions aimed at amyloid processing or secretion under defined release conditions. Researchers can ask whether changing secretase-related processing or peptide export alters downstream outcomes such as accumulation or synaptic dysfunction. This makes release regulation a bridge between molecular therapeutic targets and disease-relevant neuronal effects.
Alzheimer’s disease studies can use controlled release to connect peptide handling with neuronal function. By relating the timing or amount of Aβ available to activity-dependent signaling, accumulation, aggregation-promoting conditions, and synaptic dysfunction, investigators can separate connected stages of the process. That separation helps organize mechanistic models of how altered amyloid biology may affect neural systems.